- Eurofins MWG Operon Reinforces Next Generation Sequencing Capability with New Illumina HiSeq 2500 and Illumina MiSeq
Product News: Eurofins MWG Operon Reinforces Next Generation Sequencing Capability with New Illumina HiSeq 2500 and Illumina MiSeqEurofins MWG Operon, one of the pioneers and key providers of next generation sequencing (NGS), has added an Illumina HiSeq 2500 and an Illumina MiSeq sequencer to its fleet of NGS sequencers. With this new equipment, the company will be able to provide customers with NGS services at high accuracy rate and shorter turnaround time (TAT).
Whilst technological innovation has improved the general performance of sequencing equipment in recent years, long turnaround times remain an issue, especially in fields like personalized medicine, pharmacogenomics, marker assisted breeding, or diagnostics. A bench top sequencer such as the Illumina MiSeq, with its smaller read output (10–12 million reads), but longer read length (currently 2x 150bp, soon 2x 250bp), is the ideal tool for fast data delivery services. The rapid turnaround run mode of the HiSeq 2500 allows overnight sequencing of a human genome to 30 fold coverage.
Eurofins MWG Operon has established a solid market reputation as a premium provider for high throughput sequencing, professional project consulting, and innovative developments in library generation for a wide range of applications.
“The investment in these two new sequencers is part of Eurofins’ strategic effort to grow its sequencing capacity in line with market demand. The combination of MiSeq and HiSeq 2500 is a versatile solution to service many types of projects and customers, delivering sequencing data at low cost, high-throughput, fast turnaround time and at a high accuracy level. Eurofins will continue to expand and adapt its sequencing portfolio in response to evolving technologies and market demands, and will keep bringing innovative solutions to upcoming markets such as Diagnostics and Agrigenomics”, says Bruno Poddevin, Eurofins Senior Vice President, Genomic Services.